Cyxone AB
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, … Read more
Cyxone AB (CYXO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.163x
Based on the latest financial reports, Cyxone AB (CYXO) has a cash flow conversion efficiency ratio of -0.163x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.81 Million) by net assets (Skr29.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cyxone AB - Cash Flow Conversion Efficiency Trend (2015–2023)
This chart illustrates how Cyxone AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cyxone AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cyxone AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CENTURY ALUMINUM
BE:EY3
|
0.032x |
|
NISSAN CHEMICAL IND - Dusseldorf Stock Exchang
DU:NSC
|
0.000x |
|
China Dongsheng International Inc
PINK:CDSG
|
-0.019x |
|
SULLIDEN MNG CAPITAL
F:14S
|
N/A |
|
Morgan Sindall Group PLC
LSE:MGNS
|
-0.023x |
|
Genpact Ltd
STU:35G
|
0.090x |
|
BABW
BATS:BABW
|
N/A |
|
TOKIO MARINE
BE:MH6
|
N/A |
Annual Cash Flow Conversion Efficiency for Cyxone AB (2015–2023)
The table below shows the annual cash flow conversion efficiency of Cyxone AB from 2015 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | Skr38.96 Million | Skr-19.39 Million | -0.498x | +43.45% |
| 2022-12-31 | Skr46.95 Million | Skr-41.32 Million | -0.880x | +20.16% |
| 2021-12-31 | Skr39.23 Million | Skr-43.25 Million | -1.102x | -64.84% |
| 2020-12-31 | Skr67.11 Million | Skr-44.88 Million | -0.669x | -36.20% |
| 2019-12-31 | Skr71.74 Million | Skr-35.23 Million | -0.491x | -141.49% |
| 2018-12-31 | Skr70.55 Million | Skr-14.35 Million | -0.203x | -40.44% |
| 2017-12-31 | Skr37.13 Million | Skr-5.38 Million | -0.145x | +12.92% |
| 2016-12-31 | Skr22.83 Million | Skr-3.80 Million | -0.166x | -124.22% |
| 2015-12-31 | Skr338.00K | Skr232.00K | 0.686x | -- |